- Case Report
- Open Access
A case of non-invasive serous adenocarcinoma at unilateral fimbria with spread to the peritoneal/uterine cavity: case report
© Fukumura et al; licensee BioMed Central Ltd. 2009
- Received: 3 September 2009
- Accepted: 5 December 2009
- Published: 5 December 2009
Recently, fimbriae have been identified as a possible arising site for the pelvic serous carcinoma (PSC) both in BRCA-positive and BRCA-negative women. Although non-invasive (intraepithelial) serous adenocarcinoma of the fimbria has been found in specimens obtained from prophylactic salphingo-oophorectomies in BRCA-positive women, there has not been any case report in clinical situation, since this type of tumor is usually detected after stromal invasion/widespread dissemination. We describe a 67-year-old woman with non-invasive serous adenocarcinoma located solely in the left fimbria. This case may suggest the benefit of endometrial cytology and detailed gross examination of fimbria for the early detection of fimbrial carcinoma. This case may provide evidence suggesting fimbrial intraepithelial adenocarcinoma is one cause of PSC.
- Fallopian Tube
- Peritoneal Surface
- Serous Adenocarcinoma
- Fallopian Tube Carcinoma
Pelvic serous carcinoma (PSC) has been presumed to arise in three different locations in the female pelvis : the ovary (serous ovarian carcinoma), the endosalpinx (serous fallopian tube carcinoma) and on the peritoneal surface (primary peritoneal serous carcinoma). Among the three, primary cancer of the fallopian tube has previously been estimated to be very rare .
Recently, tubal fimbriae have been shown as the common site for early PSC (intraepithelial carcinoma) in women with BRCA mutations . Also, the potential role of the fimbriae in primary PSC has been suggested [4, 5], irrespective of BRCA-status. A few case of fimbrial adenocarcinoma, though invasive, has also been reported in surgical material resected for benign gynecological tumor at other sites .
We present a case of PSC caused by non-invasive serous adenocarcinoma involving the unilateral fimbria. To our knowledge, this is the first case report describing non-invasive, serous adenocarcinoma originating in the fimbria and spreading to the pelvic/intrauterine cavity in a clinical situation.
Because of the cytology/biopsy findings, hysterectomy and bilateral salphingo-oophorectomy with sampling of intra - pelvic lymph nodes were performed. During surgery, there were no visible lesions in the abdominopelvic space with only a small amount of yellowish to slightly muddy ascites. However, intraoperative cytology of the ascites demonstrated many adenocarcinoma nests (Fig. 1B).
Since there was no evident adenocarcinomatous lesion was on gross inspection, the whole surgical specimen was cut into histological section, in order to find the origin of the tumor. Bilateral adnexae except fimbria were cut into section at 5 mm intervals and each fimbriated end was cut sagitally into two.
Assignment of the primary site for PSCs is often problematic, since these lesions are usually discovered after spreading to the peritoneal surfaces. Our case was diagnosed to be tubal, especially, of fimbrial-origin. Surprisingly, despite the 'non-invasive' stage, our case showed spread to the peritoneal/intrauterine cavity, suggesting the ability of this type of tumor to spread rapidly. Although the peritoneum was not at all resected during surgery, the peritoneal surface is unlikely to have been primary site in our case for the following reasons. (1) There was no grossly suspicious lesion observed during the surgery. (2) Diffuse replacement of the fimbrial epithelium by the tumor and existence of a p53 signature may support the fimbria as the primary site. Only the co-exsistence of p53 signature may not be a strong evidence for its primary site without genetic testing, the diffuse replacement of the tumor suggested 'primary' rather than 'implantation'.
Until recently, most pathologists have not customarily examined the entire fallopian tube in cases of pelvic serous carcinoma, but rather only a perfunctory section of the central fallopian tube. Lee et al.  developed a protocol for sectioning and extensively examining the fimbriated end (SEE-FIM) to examine adnexal lesions thoroughly. They proposed application of this protocol to BRCA+ patients, patients with a family history of ovarian/breast cancer, and epithelial malignancies of the reproductive tract. We again recommend examining the fimbriae in PSC cases. As for the examination of routine hysterectomy cases, we think, it may be reasonable to examine bilateral fimbriae and 1 or 2 sections of bilateral tube.
As far as we know, there has no case report of serous adenocarcinoma of the fimbria at non-invasive (intraepithelial) stage, except prophylactically operated cases. In this case, the endometrial cytology contributed in the earlier detection of the fimbrial carcinoma.
In our case, there was a marked gross difference between the left fimbria (with adenocarcinoma) and the right fimbria (without), when seen observed from the back side. Detailed gross examination may be helpful for the early detection of fimbrial carcinoma. In our routine work, because of the surgical procedure, fimbriae are sometimes very much congested when submitting to pathological department. Earlier observation of fimbriae may be recommendable for their detailed gross examination.
Clinical case detecting fimbrial adenocarcinoma at intraepithelial stage is very rare. This case report may suggest the benefit of endometrial cytology, detailed examination of fimbria, and may provide evidence suggesting fimbrial intraepithelial adenocarcinoma is one cause of PSC.
Written informed consent was obtained from the patient for publication of this case report and accompanying images.
- Piek JM, Kenemans P, Verheijen RH: Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol. 2004, 191: 718-732. 10.1016/j.ajog.2004.02.067.View ArticlePubMedGoogle Scholar
- Rosen A, Klein M, Lahousen M, Graf AH, Rainer A, Vavra N: Primary carcinoma of the Fallopian tube - a retrospective analysis of 115 patients. Br J cancer. 1993, 68: 605-609.PubMed CentralView ArticlePubMedGoogle Scholar
- Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP: The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006, 30: 230-236. 10.1097/01.pas.0000180854.28831.77.View ArticlePubMedGoogle Scholar
- Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsh MS, Lee Y, Muto MG, Kindelberger D, Crum CP: Serous tubal intraepithelial carcinoma: Its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008, 26: 4160-4165. 10.1200/JCO.2008.16.4814.PubMed CentralView ArticlePubMedGoogle Scholar
- Kindelberger DW, Lee Y, Miron A, Hirsh MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP: Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007, 31: 161-169. 10.1097/01.pas.0000213335.40358.47.View ArticlePubMedGoogle Scholar
- Semmel DR, Folkins AK, Hirsh MS, Nucci MR, Crum CP: Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. Mod Pathol. 2009, 22: 985-988. 10.1038/modpathol.2009.64.PubMed CentralView ArticlePubMedGoogle Scholar
- Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP: A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007, 211: 26-35. 10.1002/path.2091.View ArticlePubMedGoogle Scholar
- Lee Y, Medeiros F, Kinderberger D, Callahan MJ, Muto MG, Crum CP: Advances in the recognition of tubal intraepithelial carcinoma. Applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol. 2006, 13: 1-7. 10.1097/01.pap.0000201826.46978.e5.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.